Quick Answer: How Do You Switch Manufacturers Without a Supply Gap?

Plan the switch around the date the new factory’s approved product can reach your selling inventory. A quoted production lead time covers only part of that window.

  • Protect the product: confirm transfer rights, freeze the approved specification and give the new factory an authorized technical brief.
  • Protect availability: include development, validation, material purchasing, production, release, transport and receiving in the stock-cover plan.
  • Control the handover: release the first new commercial lot against agreed criteria before relying on it to replace acceptable old-source supply.

Keep a fallback plan for delays, and review quality concerns separately from the pressure to stay in stock.

Switching Skincare Manufacturers A Supply Continuity Guide six step transfer infographic - Switching Skincare Manufacturers: A Supply Continuity Guide
Switching Skincare Manufacturers infographic

A manufacturing switch must preserve the approved product and a workable supply plan. This guide focuses on established cosmetic skincare SKUs, where formula access, packaging, validation and inventory have to move through a controlled handover.

Plan the Supply Window and Bridge Stock First

Appoint one transition owner and work backward from the projected date when the new product will be released, received and available for sale. Include the work still outstanding: rights clearance, sample revisions, validation, raw materials and packaging, production scheduling, quality release, freight, customs and warehouse receiving. Identify which tasks can run together and which block the next stage.

Build the stock plan for each SKU. Use sellable inventory, excluding quarantined, expired or otherwise unusable units, and account for remaining shelf life and channel requirements. A large total stock number can hide a shortage of the bestselling size or pack.

Additional bridge-stock estimate: forecast demand until new supply is available, plus a chosen safety buffer, minus usable stock and reliable incoming old-source stock. Treat a negative result as zero additional units for this estimate.

For illustration, 50 units of daily demand over a remaining 90-day window equals 4,500 units. Add a 1,000-unit buffer and subtract 3,000 usable units: with no other inbound stock, the estimated bridge requirement is 2,500 units. These figures illustrate the calculation, not a recommended transfer duration or buffer.

Check the calculation against a dated weekly stock ledger. An inbound order arriving after stock runs out cannot prevent the earlier gap. Recalculate when approvals, forecasts or delivery dates change, and agree whether acceptable old-source replenishment, a phased SKU switch or reduced promotions is feasible.

Overlap production only while old-source supply remains suitable for release. Suspected safety problems, contamination or failed specifications need quality assessment and appropriate stock controls; buying more of that product is not a continuity solution.

Six Steps to Switch Skincare Manufacturers

Step 1: Confirm Your Transfer Rights and Product Route

Review the current agreement before sharing technical files or setting an exit date. Confirm the rights to disclose and manufacture the formula, access to process information, packaging and tooling ownership, notice periods and outstanding commitments. Confidential formulas and manufacturing know-how can be protected trade secrets; transfer or licensing authority needs to be established.[1]

Choose the route that matches what you can lawfully provide:

Transfer routeStarting pointConsequence for the project
Brand-owned formula transferDocumented rights to the formula and access to the necessary manufacturing informationAssess whether the receiving factory can reproduce the approved product and validate its process
Licensed formula transferWritten permission covering the receiving manufacturer and intended useConfirm the license scope, access conditions and any restrictions before disclosure
New formulation against a benchmarkAn authorized product brief or benchmark, with a separately reviewed development scopeTreat the result as development work; matching an ingredient label does not establish an identical product

A development payment or ownership of the brand name should not be treated as proof of every transfer right. An NDA protects confidentiality; it does not by itself settle formula ownership or grant a manufacturing license. Resolve disputed formula ownership before moving confidential information.[1]

Step 2: Freeze the Specification and Build the Transfer File

Create a controlled baseline for the SKU before the new factory starts work. Identify the approved formula version, pack configuration, label and claims, reference samples and acceptance criteria. Separate requirements that must remain unchanged from improvements that can wait until after the transfer.

A reproducible manufacturing brief needs more than a consumer ingredient list. Formula quantities, raw-material grades, processing instructions and equipment requirements help explain how the product is made; changing scale and equipment introduces additional variables.[2]

Request the records you are entitled to access, and mark gaps openly:

  • Formula and process: authorized composition, raw-material specifications, order of addition and important mixing, heating, cooling or hold conditions.
  • Product and evidence: the finished-product specification, agreed test methods, representative batch records or results, relevant safety and stability evidence, and known complaints or recurring defects.
  • Packaging and approvals: component drawings, materials, decoration files, closures, fill and dosing requirements, coding rules and the people authorized to approve changes.

Use recent, traceable reference samples and the written specification together. A single aged sample should not become the sole standard. Give every file a version and owner so both factories are not working from different definitions of the same SKU.

Step 3: Qualify the New Factory and Reproduce the Product

Confirm that the new site can support the actual product category, process, batch size, filling and packaging requirements. Review relevant quality controls, records and capacity using a focused manufacturer assessment; a successful sales discussion does not establish production readiness.

Compare development samples with the baseline using agreed methods and conditions. Evaluate appearance, odor, application, after-feel and relevant measurements such as pH or viscosity. Record and resolve differences before sample approval.

Plan a suitable pilot or representative manufacturing run before depending on commercial output. Mixing, heating and cooling behave differently at scale, so a good laboratory sample does not establish that a different factory process will produce the same result.[2] The pilot-batch and scale-up stage should produce evidence against the agreed acceptance criteria.

Approve changes in writing. Substituting a raw-material grade, pump or preservative system during transfer creates another variable to assess, even when the product name stays the same.

Step 4: Complete Validation and Market-Readiness Checks

Have the appropriate technical and quality reviewers assess which existing evidence remains applicable and what the transfer changes. Agree the necessary stability, packaging compatibility, microbiological, preservative-efficacy and claim-support work for the actual formula, process and final pack. Keep the roles of stability, compatibility and challenge testing distinct.

For U.S. cosmetics, there is no single FDA-prescribed test list for every product. Relevant existing safety data can contribute to the assessment, while evidence gaps may require additional work. The decision should rest on scientifically sound support, not the assumption that either every test must restart or no retesting is needed.[3]

Assign someone to review the destination-market consequences of the new site, formula, pack or claims. For U.S. products, check applicable facility registration and product-listing information, responsible-party duties and exemptions. Registration or listing does not mean FDA approval; use the MoCRA checklist for the wider requirements.[4]

Products with drug uses require their own transfer assessment. For example, U.S. moisturizers with sun-protection claims are cosmetic/drug products, and cosmetic-only assumptions do not cover all their obligations.[5]

Record the release basis, unresolved items, continuing studies where justified, and who can authorize commercial release. A deadline must not substitute for missing safety or quality support.

Step 5: Receive and Release the First Commercial Order

Place the first commercial order against the approved formula, packaging, specification and responsibilities. Confirm production and dispatch milestones, but keep the cutover tied to released inventory reaching the destination. A finished batch awaiting approval, or a shipment still in transit, is not available stock.

Before the new lot becomes the main supply, confirm:

  • Product acceptance: required results and records meet the agreed criteria, with deviations resolved or formally assessed by the authorized quality reviewer.
  • Pack and identity: filling, dispensing, seals, artwork, batch codes and component versions match the approved configuration.
  • Arrival and accountability: receiving checks are complete, lot identity is preserved, and responsibilities for complaints, investigations and stock decisions are clear.

Keep the option to delay the cutover if a gate fails. Choose a feasible first-order size and an inventory buffer that leave room to respond to problems without creating excessive obsolete stock.

Step 6: Complete the Cutover and Monitor Repeat Production

Confirm that new supply is accepted and the follow-up production plan is credible before retiring acceptable old-source replenishment. Honor the notice arrangements reviewed at the start, settle outstanding commitments, and document the disposition of remaining raw materials, printed packaging, tooling and approved records. Keep access to the information needed to investigate earlier lots.

Track complaints, returns, dispensing performance and agreed quality results by manufacturer and lot. Compare repeat production against the approved standard through a batch-consistency review; do not rely only on the first development sample.

Close the transition when the agreed quality, supply and document handover criteria are met. Set the monitoring window for the product and risk. Keep any justified ongoing stability work and routine quality controls active after the commercial handover.

Discuss Your Skincare Manufacturing Transition

ZICAIL offers OEM/ODM skincare development support covering product direction, sampling and packaging coordination. For a proposed transition, prepare your SKU list, target markets, transfer-rights position, accessible specifications, packaging details, expected volumes and stock-cover deadline. Feasibility, development needs and testing scope should be confirmed before a production date is committed.

Discuss your manufacturing transition to establish the next review and sampling step.

FAQs About Switching Skincare Manufacturers

Can a new manufacturer make exactly the same formula?

An authorized formula transfer can aim to reproduce the approved product, but access to the formula alone does not establish identical manufacturing results. Raw-material grades, processing and packaging also matter. A benchmark or ingredient label is a starting point for development, not proof of an exact copy.

How long does switching skincare manufacturers take?

There is no reliable universal timeline. Count the remaining work through validation, material availability, production, release, freight and receiving. An accessible formula and unchanged pack can simplify the project; missing rights, new development or additional evidence can extend it.

Do all tests need to be repeated after changing factories?

Not automatically. Review whether earlier data still support the transferred formula, process and pack, then address the gaps. Equally, keeping the same product name or ingredient list does not justify assuming every old result transfers unchanged.[3]

What if the current manufacturer will not share the formula?

Check the agreement and your disclosure rights before treating refusal as a breach. If you lack transfer permission, explore an agreed license, acquisition of rights or a separate development project. Do not send confidential files to another factory without authority.[1]

Sources

[1] World Intellectual Property Organization. Frequently Asked Questions: Trade Secrets

[2] The Ordinary / DECIEM. From Formula to Face: How Skincare is Developed at Scale

[3] U.S. Food and Drug Administration. Product Testing of Cosmetics

[4] U.S. Food and Drug Administration. Registration & Listing of Cosmetic Product Facilities and Products

[5] U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)